CurePSP awards three new Venture Grants for the study of PSP and CBD
Studies will focus on toxic protein in the brain and genetic factors
News provided by
Share this article
Share this article
NEW YORK, April 15, 2021 /PRNewswire/ CurePSP has awarded Venture Grants to three researchers studying tau protein pathology and genetic factors in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Each grant is for $100,000.
Dr. Rohan de Silva of UCL Queen Square Institute of Neurology in London has received a grant for his study of the propagation of toxic tau protein in the brain. The aim of this project is to understand how healthy tau is converted to toxic strains related to PSP and CBD and to identify their imprinted defects that enable the strain-specific progression. As Dr. de Silva explains, Tau protein is essential for healthy nerve cells, but tau gone bad drives the devastating damage and progression of PSP, CBD, and other diseases involving the tau